WEBULL

Analysts Expect Nicox S.A. (EPA:ALCOX) To Breakeven Soon

Simply Wall St · 01/06 04:01

Nicox S.A. (EPA:ALCOX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The €28m market-cap company posted a loss in its most recent financial year of €22m and a latest trailing-twelve-month loss of €27m leading to an even wider gap between loss and breakeven. As path to profitability is the topic on Nicox's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Expectations from some of the French Biotechs analysts is that Nicox is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of €8.0m in 2026. Therefore, the company is expected to breakeven roughly a year from now or less! We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 179% is expected, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

earnings-per-share-growth
ENXTPA:ALCOX Earnings Per Share Growth January 6th 2026

Given this is a high-level overview, we won’t go into details of Nicox's upcoming projects, but, take into account that typically a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Check out our latest analysis for Nicox

One thing we would like to bring into light with Nicox is it currently has negative equity on its balance sheet. This can sometimes arise from accounting methods used to deal with accumulated losses from prior years, which are viewed as liabilities carried forward until it cancels out in the future. These losses tend to occur only on paper, however, in other cases it can be forewarning.

Next Steps:

This article is not intended to be a comprehensive analysis on Nicox, so if you are interested in understanding the company at a deeper level, take a look at Nicox's company page on Simply Wall St. We've also put together a list of essential factors you should further examine:

  1. Historical Track Record: What has Nicox's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Nicox's board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.